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outcomes, the main fields covered by PROs (such as quality of life) in 
chronic diseases will be described. We will develop PRO measurement 
issues, notably psychometric properties and cultural adaptations, and 
also differences between generic and disease-specific instruments, 
with quality of life instruments as an example. Then we will define 
the use of PROs data in the field of adherence research, with their 
advantages and limitations compared with other sources of data. 
Last, the actual or potential impact of PROs will also be examined in 
terms of quality of care for daily medical practice and research issues.
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Summary: The new manifesto on clinical pharmacology (CP) empha-
sizes the importance of CP in delivery of health care, the role of CP 
that has not always been played the way and in the extent it was 
hoped for. In Croatia, CP has been recognized as a separate medical 
discipline/specialty since 1974. Since then, > 30 physicians have been 
trained in CP and work in various health care settings across country. 
Depending on the setting, they provide CP services, conduct research, 
and are involved in teaching. In some settings, clinical pharmacolo-
gists provide direct patient care, having a direct responsibility for 
patients, but more commonly provide a range of services to clinical 
colleagues and their patients as well as serve as consultants in regula-
tory and administrative bodies dealing with medications. Although 
specialists in CP, not all clinical pharmacologists involved in health 
care belong to established departments/units of CP. Differences in 
organizational models for delivering CP services to health care prob-
ably arise from not adequately defined functions of CP. The functions 
have been well defined in the new Manifesto but not well recognized 
by relevant bodies. We should not be ignoring the challenging future 
of CP in health care.
Disclosure of Interest: None declared.
The SCoTTiSh model: SCoTTiSh mediCiNeS 
CoNSorTium (SmC)
D.J. Webb*
Pharmacology Toxicology & Therapeutics, University of 
Edinburgh, Edinburgh, United Kingdom
Summary: UK health care is provided by a national health service 
(NHS), within which medicines are a major and growing cost. 
Concerns from patients, politicians, medical practitioners, and the 
press about “postcode” prescribing (marked regional differences 
in availability of newly licensed medicines) led to the creation of 
the Scottish Medicines Consortium (SMC). Run by NHS clini-
cians, SMC provides rapid advice on all new medicines, including 
new indications/formulations for existing therapies. A streamlined 
2-stage pharmacy and health economic, and then strategic, review 
of submissions from industry by SMC provides an objective review 
of the data and a wider societal view of need. A patient perspec-
tive is included. Comparative cost-effectiveness is assessed, prefer-
ably by using QALY ICERs, and advice given close to UK licensing 
(usually within 4 months). This early advice means that physicians 
are prepared to wait for the decision from SMC, and prescribing 
is relatively uncommon outside the guidance. Three outcomes are 
possible: (1) accept for general use; (2) accept with restriction (by 
specialist prescriber, or only for a subgroup within the license); or 
(3) do not recommend for use in Scotland. Appeals can be heard and 
resubmissions can be made if the evidence base changes. Around 
1000 submissions have now been made, including abbreviated sub-
missions for minor license changes, since 2002. Around two thirds of 
all medicines were accepted for use in NHS Scotland but many in a 
way more restrictive than the license. Around 50% of resubmissions 
are accepted. Evidence suggests SMC decisions are not influenced by 
budget impact (affordability) but are strongly influenced by whether 
the drug provides value for money to the NHS in Scotland. Accepted 
modifiers of decisions include orphan indications, end-of-life treat-
ment, bridging to a definitive treatment, and the development of 
licensed treatment where only an unlicensed preparation previously 
existed. Drug utilization data suggest that early advice influences 
prescribing patterns, in a positive way for approved drugs, and by 
lack of uptake (or reduction of existing prescribing) for those not rec-
ommended (with some exceptions). Benchmarking shows a high level 
of consistency with subsequent decisions from the National Institute 
for Health and Clinical Excellence (NICE), and the Pharmaceutical 
Benefits Advisory Committee (PBAC) in Australia. SMC has an ongo-
ing horizon scanning program, created a Scottish Management of 
Antimicrobial Resistance action Plan (ScotMARAP; 2008), and now 
runs a Patient Access Scheme to make high-cost drugs affordable 
to Scottish patients. An open and inclusive process, involving key 
stakeholders, can produce useful, rigorous, evidence-based advice 
to a health care system in a way that is acceptable to the NHS and to 
the pharmaceutical industry, and occurs sufficiently early after the 
launch of a new drug to inform and influence subsequent prescrib-
ing patterns.
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Summary: Despite being 1 of the most prevalent tropical diseases, for 
many years malaria was not a commercial priority for the pharma-
ceutical industry. However, in response to the emergence and spread 
of resistance to the available antimalarial drugs, there has been a 
renaissance in the discovery and development of new medicines to 
control the disease in the last few years. The persistent threat of 
resistance means that new molecules with novel mechanisms of action 
are continually required. Furthermore, the recent call for the elimi-
nation and eradication of malaria has prompted an extension of the 
stages of the life cycle of malaria parasites that should be targeted 
by new molecules. Recent advances in genome-based technologies 
and in vitro screening of whole parasites have broadened the range 
of therapeutic targets and are accelerating the development of a new 
generation of treatments for both malaria control and eradication.
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Summary: The purpose of regulatory toxicology is to evaluate all 
available information relevant to the toxicity of agents, which may 
be biological, chemical, or physical in nature, on behalf of govern-
mental or international organizations. The aim is to protect workers, 
consumers, the public generally, and the environment. Wherever pos-
sible, this is done through a process of quantitative or qualitative risk 
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assessment (RA), which involves examining the intrinsic toxicity of 
an agent (hazard assessment) and comparing it with the anticipated 
human exposure to characterize the likelihood of adverse effects (risk 
characterization). Although this process is meant to integrate all data 
sources (human, environmental, in vivo, in vitro, in silico), in practice 
existing regulations of pharmaceutical and chemical substances con-
tinue to ask for sector-specific RAs, each of which has its own specific 
information requirements and uses different methods for the ultimate 
risk quantification. Although regulators often stress the primacy of 
human data, in practice their use is constrained by availability and 
lack of defined quality criteria. There have been some efforts in the 
past to develop frameworks for the use of human data (eg, from 
poison centers) for risk assessment purposes. However, these have 
had only limited success. More recently, integrated approaches have 
been developed using information from animal studies and human 
data based on mode of action and weight of evidence concepts. These 
approaches need to be tested and validated. Harmonized data col-
lection based on defined quality criteria is a precondition for better 
use of human data in risk assessment. It will only become a reality if 
existing networks of institutions such as poison control and clinical 
toxicology centers are being strengthened and, importantly, if they 
interact with regulatory decision makers on a regular basis. This 
will result in enhanced sharing of knowledge, build consensus, and 
facilitate clear, easily understood, transparent, and unambiguous inte-
grated RA procedures. Network initiatives such as the EU FP7 project 
HEROIC aim to contribute to the development of such harmonized 
approaches that meet the challenges of RA.
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Clinical pharmacology in Russia was established 13 years after the 
first World Health Organization (WHO) manifesto describing its 
duties was released. In 1983, it was defined as a separate educational 
discipline in medical universities. Starting from 1997, the medical 
specialty “clinical pharmacologist” was established, and its func-
tions were defined. It was built on the union of pharmacology and 
internal medicine, and that is why clinical pharmacology in Russia 
is characterized by close proximity to routine patient care. A clini-
cal pharmacologist in Russia should first receive training in internal 
medicine and then 2-year specialization in clinical pharmacology. 
The current main duties of clinical pharmacologists in Russia are 
defined by the ministerial laws released in 2003 and 2010, updated 
in 2012. According to these documents, clinical pharmacologists 
should see patients and be able to adjust treatment by taking into 
account various possible factors of individual response to medica-
tions. They should advise when necessary and interpret results of 
pharmacogenetic analyses; perform therapeutic drug monitoring and 
drug interaction analyses; and diagnose, register, and manage adverse 
drug reactions. Furthermore, clinical pharmacologists should manage 
quality control of medications used in their hospitals, participate in 
drug and therapeutics committees, develop and maintain a system of 
formulary lists of medications, perform drug utilization surveillance, 
participate in microbiology monitoring in relation to antibiotic utili-
zation, define economic feasibility of different medications use, and 
approve purchase of drugs according to the general hospital needs. 
They should also provide informational services to physicians and 
patients on various issues of rational drug use.
According to the current law, every medical institution should 
have a position of clinical pharmacologist; hospitals with > 500 
beds are advised to have a corresponding division. This provides 
grounds for active development of the specialty and improvement 
of educational programs. Some universities have courses of clini-
cal pharmacology included in the curriculum of other specialists. 
Since 2009, clinical pharmacologists in Russia are cooperating 
within the all-Russian “Association of Clinical Pharmacologists” 
comprising the vast majority or regions. The association is per-
forming important organizational, informational and expert func-
tions.
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Summary: To clarify the potential association between diabetes, 
related factors, treatments, and breast cancer risk, a series of meta-
analyses was carried out following PRISMA guidelines. For breast 
cancer at all ages, the risks obtained from prospective studies were: 
diabetes (SRR = 1.27 [95% CI, 1.16 to 1.39]); physical activity (SRR 
= 0.88 [0.85 to 0.92]); glycemic load (SRR = 1.05 [1.00 to 1.10]); 
glycemic index (SRR = 1.05 [1.00 to 1.09]); fasting glucose (SRR 
= 1.14 [0.94 to 1.37]); serum insulin (SRR = 1.11 [0.75 to 1.85]); 
c-peptide (SRR = 1.00 [0.69 to 1.46]), and adiponectin (SRR = 1.16 
[0.93 to 1.46]). An increase of 5 units in BMI was associated with 
postmenopausal breast cancer (SRR = 1.12 [95% CI, 1.08 to 1.16]) 
but not at premenopausal ages (SRR = 0.83 [95% CI, 0.72 to 0.95]). 
Serum insulin and c-peptide were associated with breast cancer at 
postmenopausal ages but not at premenopausal. For IGF-1, Hodge’s 
standardized mean difference (HSMD) was calculated, and there was 
no significant association with breast cancer (HSMD = 0.026 [95% 
CI, –0.031 to 0.084]).
The SRR for breast cancer among users of insulin glargine was 
1.08 (0.98 to 1.20) and was 0.92 (0.32 to 2.65) when restricted to 
randomized trials. Among new users, the SRR for breast cancer was 
1.09 (0.98, 1.21), and there was no trend of increasing breast cancer 
risk with increasing duration of use of glargine (β = 0.04) (P = 0.52). 
Risk of breast cancer in a prospective cohort declined with increasing 
follow-up, from 1.99 (1.31, 2.03) with 2 years of follow-up, to 1.60 
(1.10 to 2.32) with 3 years, 1.50 (1.10 to 2.10) with 4 years and 1.18 
(0.84 to 1.66) with 5 years of follow-up. There is no reduction in risk 
of breast cancer associated with metformin use (SRR = 0.96 [95% 
CI, 0.85 to 1.08]) even for the longest duration of use (SRR = 0.94 
[95% CI, 0.81 to 1.09]).
An association between these 2 common diseases could have 
important implications for public health, with common risk factors 
